We are live on
!
Find out more
EAM
Exome Asset Management Portfolio holdings
AUM
$193M
1-Year Est. Return
208.51%
This Fund
S&P 500
This Quarter
Est. Return
+10.44%
1 Year Est. Return
+208.51%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$135M
AUM Growth
+$22M
(+20%)
Cap. Flow
+$60.5M
Cap. Flow
% of AUM
44.95%
Top 10 Holdings %
Top 10 Hldgs %
36.29%
Holding
86
New
27
Increased
9
Reduced
17
Closed
23
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tenet Healthcare
THC
|
+$4.06M |
| 2 |
Verastem
VSTM
|
+$3.76M |
| 3 |
Praxis Precision Medicines
PRAX
|
+$2.25M |
| 4 |
APLS
Apellis Pharmaceuticals
APLS
|
+$1.83M |
| 5 |
Universal Health Services
UHS
|
+$1.82M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AKRO
Akero Therapeutics
AKRO
|
+$3.47M |
| 2 |
Viridian Therapeutics
VRDN
|
+$2.93M |
| 3 |
Savara
SVRA
|
+$2.32M |
| 4 |
AstraZeneca
AZN
|
+$2.28M |
| 5 |
AnaptysBio
ANAB
|
+$2.13M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 79.82% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
CALL
UnitedHealth
UNH
$382B
| $437K | 0.32% |
+1,400
| New | +$535K |
|
52
PUT
Altimmune
ALT
$568M
| $414K | 0.31% |
+107,000
| New | +$579K |
|
|
YARW
53
Yarrow Bioscience, Inc. Common Stock
YARW
$20.3M
| $345K | 0.26% |
4,179
-5,077
| -55% | -$330K |
|
54
Instil Bio
TIL
$49M
| $337K | 0.25% |
+16,200
| New | +$339K |
|
|
55
AnaptysBio
ANAB
$1.54B
| $333K | 0.25% |
15,000
-101,623
| -87% | -$2.13M |
|
56
Eledon Pharmaceuticals
ELDN
$255M
| $309K | 0.23% |
114,145
| – | – |
|
57
Liquidia Corp
LQDA
$7.72B
| $255K | 0.19% |
+20,500
| New | +$304K |
|
58
Arbutus Biopharma
ABUS
$847M
| $233K | 0.17% |
+75,484
| New | +$251K |
|
59
CALL
Fulcrum Therapeutics
FULC
$241M
| $138K | 0.1% |
+20,000
| New | +$107K |
|
|
ELEV
60
DELISTED
Elevation Oncology
ELEV
| $40.5K | 0.03% |
+110,353
| New | +$36.8K |
|
|
MREO
61
PUT
Mereo BioPharma
MREO
$48.9M
| $39.6K | 0.03% |
+14,600
| New | +$35.2K |
|
62
Akebia Therapeutics
AKBA
$338M
| – | – |
-189,087
| Closed | -$363K |
|
|
AKRO
63
DELISTED
Akero Therapeutics
AKRO
| – | – |
-76,379
| Closed | -$3.47M |
|
64
PUT
Aldeyra Therapeutics
ALDX
$97.1M
| – | – |
-100,000
| Closed | -$190K |
|
65
Aprea Therapeutics
APRE
$7.69M
| – | – |
-28,972
| Closed | -$59.1K |
|
66
Arvinas
ARVN
$530M
| – | – |
-195,295
| Closed | -$1.37M |
|
|
67
AstraZeneca
AZN
$269B
| – | – |
-16,267
| Closed | -$2.28M |
|
68
Biohaven
BHVN
$2.02B
| – | – |
-39,900
| Closed | -$959K |
|
69
PUT
Cytokinetics
CYTK
$10.6B
| – | – |
-23,000
| Closed | -$141K |
|
70
GE HealthCare
GEHC
$32.5B
| – | – |
-25,400
| Closed | -$2.05M |
|
71
CALL
Gossamer Bio
GOSS
$101M
| – | – |
-100,000
| Closed | -$47.5K |
|
72
Immunome
IMNM
$2.62B
| – | – |
-263,841
| Closed | -$1.78M |
|
73
Nektar Therapeutics
NKTR
$2.39B
| – | – |
-148,830
| Closed | -$1.67M |
|
74
Nuvation Bio
NUVB
$2.29B
| – | – |
-96,311
| Closed | -$170K |
|
75
Dr. Reddy's Laboratories
RDY
$9.8B
| – | – |
-117,500
| Closed | -$1.55M |
|
Similar funds
WWC
JHA
TDWM
DF
SCM
PA
SCPM
EWM
Exome Asset Management's Q2 2025 Portfolio in Review
As of Q2 2025, Exome Asset Management held 86 positions worth $135M, up 20% from $112M the previous quarter. Its ten largest holdings account for 36% of the portfolio.
Exome Asset Management deployed $60.5M of net new capital in Q2 2025, opening 27 new positions and adding to 9 existing holdings. Its largest new stake was Tenet Healthcare: 27,000 shares worth $4.75M.
By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 98% a quarter earlier.
On the sell side, the largest reduction was AnaptysBio, an estimated $2.13M trimmed.
- Exome Asset Management's largest Q2 2025 buy was Tenet Healthcare: 27,000 shares worth $4.75M.
- Exome Asset Management added most to BioCryst Pharmaceuticals in Q2 2025, an estimated $1.05M increase.
- Exome Asset Management's biggest Q2 2025 reduction was AnaptysBio, cutting an estimated $2.13M.
- Exome Asset Management fully exited Akero Therapeutics in Q2 2025, selling an estimated $3.47M.
- Exome Asset Management's ten largest holdings make up 36% of its $135M portfolio in Q2 2025.
- Exome Asset Management opened 27 new positions and closed 23 in Q2 2025.
- Exome Asset Management's portfolio value rose 20% quarter-over-quarter to $135M.
Based on Exome Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.